Search

Search bills, members, committees and pages...

Sign In

H.R. 1492

U.S. House•In House Committee

Summary

H.R. 1492, to amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program, was introduced in the House on Feb 21, 2025 by Rep. Greg Murphy (R) with 68 co-sponsors. It was referred to Energy And Commerce, and last saw action on Feb 21, 2025: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Record

Text

H.R. 1492 has 68 co-sponsors.

hb1492/introduced-in-house.txt
119 HR 1492 IH: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
 U.S. House of Representatives
 2025-02-21
 text/xml
 EN
 Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
 I  119th CONGRESS  1st Session  H. R. 1492  IN THE HOUSE OF REPRESENTATIVES   February 21, 2025   Mr. Murphy  (for himself,  Mr. Davis of North Carolina , and  Mr. Hudson ) introduced the following bill; which was referred to the  Committee on Energy and Commerce , and in addition to the Committee on  Ways and Means , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned   A BILL
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
1.
Equalizing the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program
(a)
In general
Section 1192(e)(1)(A)(ii) of the Social Security Act ( 42 U.S.C. 1320f–1(e)(1)(A)(ii) ) is amended by striking  7 years  and inserting  11 years .
(b)
Effective date
The amendment made by subsection (a) shall take effect as if included in the enactment of  Public Law 117–169 .

Tracker

The tracker indicates the progress of this legislation as it moves through the legislative process.

  1. Introduced2025-02-21
  2. Passed House
  3. Passed Senate
  4. Conference
  5. To President
  6. Became Law

CRS Summary

The summaries are the Congressional Research Service’s, one per stage. Read them in full.

Introduced in House Feb 21, 2025

hb1492/introduced-in-house.md

Shown Here:
Introduced in House (02/21/2025)

This bill lengthens the amount of time for which drug products must have market approval in order for the products to qualify for negotiation under the Medicare Drug Price Negotiation Program.

The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.

The bill modifies these provisions so as to require drug products to also have had at least 11 years of market approval in order to qualify for negotiation.

The bill's changes apply retroactively.

Sponsors

Rep. Greg Murphy (R) sponsors H.R. 1492, and 68 members have co-sponsored it, 2 of them from the day it was introduced.

Committees

H.R. 1492 went before 2 committees: Ways and Means and Energy and Commerce.

Ways and Means
Ways and Means
Referred To · Feb 21, 2025 · 1,160 Bills
Energy and Commerce
Energy and Commerce
Referred To · Feb 21, 2025 · 1,636 Bills

Actions

H.R. 1492 has taken 2 actions since Feb 21, 2025.

ChamberAction
Feb 21, 2025
House
Introduced in House
Feb 21, 2025
House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.Energy and Commerce Committee

Votes

H.R. 1492 has not gone to a roll call.

Titles

H.R. 1492 goes by 2 titles.

  • To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. — Display Title
  • To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. — Official Title as Introduced

Lobbying

54 clients hired 53 firms and 303 registered lobbyists who named H.R. 1492 in 312 quarterly filings, 2025 to 2026. Reported under the Lobbying Disclosure Act; a filing’s income covers everything its registrant worked that quarter, so the amounts below are the filings’, not this bill’s.

Filed under Health Issues, Medicare/Medicaid, Trade (domestic/foreign), Taxation/Internal Revenue Code, Copyright/Patent/Trademark, Budget/Appropriations, Pharmacy, Labor Issues/Antitrust/Workplace.

Clients

Who paid to be heard, by how many filings named the bill. The 20 that filed most often, of 54.

ClientBusinessStateFirmsFilingsReported
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICATrade association representing the nation's leading biopharmaceutical research companies.District of Columbia840$1.6M
NOVARTISInnovative medicines company.District of Columbia213$280K
PHRMARepresents country's leading pharmaceutical research and biotechnology companiesDistrict of Columbia311$630K
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA)trade group representing U.S. pharmaceutical research and biotechnology companiesDistrict of Columbia211$410K
BAYER CORPORATION (CONSOLIDATED REPORT)—District of Columbia19—
GILEAD SCIENCES, INC.Client is a biopharmaceutical company that develops medicines in areas of unmet need.California28$480K
SANOFI U.S. SERVICES, INC.Multinational Pharmaceutical Company.District of Columbia28$460K
BOEHRINGER INGELHEIM USA CORPORATIONLobbyistsDistrict of Columbia18—
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATIONPharmaceutical Industry Labor Management Association.Virginia27$350K
SOLENO THERAPEUTICS, INC.Soleno is focused on development of novel therapeutics for treatment of rare diseases.California27$170K
AMGEN INC—District of Columbia17—
GSK (FKA GLAXOSMITHKLINE INC.)—District of Columbia17—
LUNDBECK LLC—District of Columbia17—
PTC THERAPEUTICS, INC.Biopharmaceutical company.New Jersey27—
PUBLIC CITIZEN—District of Columbia17—
NOVO NORDISK, INC.Pharmaceutical company.District of Columbia16$480K
AMGEN USA INC.Biotechnology company.District of Columbia16$360K
GENENTECH, INC.Biotechnology company.District of Columbia16$360K
PFIZER, INC.Biopharmaceutical manufacturing.District of Columbia16$360K
PFIZER INC.Biopharmaceutical company.District of Columbia26$80K

Firms

Registrants who filed on the bill, by filings.

RegistrantClientsFilingsReported
MARSHALL & POPP, LLC631$1.7M
THE MCMANUS GROUP522$1.3M
THE NICKLES GROUP, LLC211$770K
W STRATEGIES, LLC511$570K
BAYER CORPORATION (CONSOLIDATED REPORT)19—
BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC18—
NOVARTIS18—
ADVANCED POLICY CONSULTING, LLC17$280K
AMGEN, INC.17—
GSK (FKA GLAXOSMITHKLINE INC.)17—
LUNDBECK LLC17—
PUBLIC CITIZEN17—
ACADIA PHARMACEUTICALS16—
AEGIS LLC16$360K
BIOTECHNOLOGY INNOVATION ORGANIZATION16—
DLA PIPER LLP (US)26$340K
E3 STRATEGIC CONSULTING GROUP16$320K
EMD SERONO, INC.16—
HEALTHCARE INSTITUTE OF NEW JERSEY16—
JOHNSON & JOHNSON SERVICES, INC.16—

Lobbyists

Named on the filings that cite the bill. The 20 named most often, of 303.

LobbyistFirmsClientsFilings
HAZEN MARSHALL1631
MONICA POPP1631
JOHN MCMANUS1522
BRETT BAKER1211
DARREN WILLCOX1511
GREG D'ANGELO1211
MARY SAVARY TAYLOR1211
RACHEL JONES HENSLER1211
ALEX WHALEN129
BRIAN NAGLE119
ERICK LUTT119
JIM TRAVIS119
MICHAEL HOLLAND119
MICHAEL PARRISH119
STEPHANIE MURPHY119
COURTNEY LEE-ASHLEY118
COURTNEY PIRON118
JOSEPH MCGOWAN118
KATHARINE BOND118
SARAH DURR118

Filings

The documents themselves, on the Senate’s Lobbying Disclosure site, largest reported first.

ClientRegistrantPeriodReportedDocument
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAPHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA2025 first_quarter$12.9M1st Quarter - Report
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAPHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA2026 first_quarter$12.2M1st Quarter - Report
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAPHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA2025 third_quarter$9M3rd Quarter - Report
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAPHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA2025 fourth_quarter$8.4M4th Quarter - Report
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAPHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA2025 second_quarter$7.6M2nd Quarter - Report
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAPHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA2026 second_quarter$7.4M2nd Quarter - Report
AARPAARP2025 fourth_quarter$5.3M4th Quarter - Report
AARPAARP2025 second_quarter$5.1M2nd Quarter - Report
MERCK & CO INCMERCK & CO, INC.2025 second_quarter$5M2nd Quarter - Amendme…
MERCK & CO INCMERCK & CO, INC.2025 second_quarter$5M2nd Quarter - Report
BRISTOL-MYERS SQUIBB COMPANYBRISTOL-MYERS SQUIBB COMPANY2025 second_quarter$4.8M2nd Quarter - Report
PFIZER INC.PFIZER INC.2025 first_quarter$4.2M1st Quarter - Report
NOVARTISNOVARTIS2025 first_quarter$4.2M1st Quarter - Report
NOVARTISNOVARTIS2026 first_quarter$3.9M1st Quarter - Report
AARPAARP2025 third_quarter$3.8M3rd Quarter - Report
PFIZER INC.PFIZER INC.2025 second_quarter$3.7M2nd Quarter - Amendme…
PFIZER INC.PFIZER INC.2025 second_quarter$3.7M2nd Quarter - Amendme…
AMGEN INCAMGEN, INC.2025 first_quarter$3.6M1st Quarter - Report
AMGEN INCAMGEN, INC.2025 fourth_quarter$3.6M4th Quarter - Report
AMGEN INCAMGEN, INC.2025 third_quarter$3.6M3rd Quarter - Report

Classification

The Congressional Research Service files H.R. 1492 under Health, one of its 31 policy areas, and gives it 3 legislative subjects.

CRS Subjects

CRS assigns every bill one policy area from its 31; H.R. 1492’s is Health.

hr1492/policy-areas.txt
HealthAgriculture and FoodAnimalsArmed Forces and National SecurityArts, Culture, ReligionCivil Rights and Liberties, Minority IssuesCommerceCongressCrime and Law EnforcementEconomics and Public FinanceEducationEmergency ManagementEnergyEnvironmental ProtectionFamiliesFinance and Financial SectorForeign Trade and International FinanceGovernment Operations and PoliticsHousing and Community DevelopmentImmigrationInternational AffairsLabor and EmploymentLawNative AmericansPublic Lands and Natural ResourcesScience, Technology, CommunicationsSocial WelfareSports and RecreationTaxationTransportation and Public WorksWater Resources Development

Legislative Subjects

H.R. 1492 carries 3 of CRS’s legislative subjects, from Health care costs and insurance to Prescription drugs.

hr1492/subjects.txt
Health care costs and insuranceMedicarePrescription drugs

Constitutional authority

The clause the sponsor cites as Congress’s power to enact H.R. 1492, as entered in the Congressional Record.

[Congressional Record Volume 171, Number 35 (Friday, February 21, 2025)][House]From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]By Mr. MURPHY:H.R. 1492.Congress has the power to enact this legislation pursuantto the following:Article 1, Section 8[Page H730]

Source: congress.gov · legiscan.com